August 22, 2008
Prometheus Granted US Patent Related to Inflammatory Bowel Disease Treatment
Prometheus Laboratories has received a new US patent related to the protection of a flagellin peptide useful in the detection of antibodies to the flagellin CBir1, or anti-CBir1, for determining the presence of inflammatory bowel disease.
Prometheus said that this proprietary technology is used in the company's Prometheus IBD serology 7 test and its recently launched Prometheus IBS diagnostic test. Prometheus has exclusive rights to this technology under an agreement with Corixa.
Prometheus IBS diagnostic is said to be the first blood-based biomarker test to help physicians diagnose irritable bowel syndrome (IBS). Prometheus said that its IBD serology 7 is the most comprehensive inflammatory bowel disease (IBD) diagnostic testing service available to help physicians detect IBD and differentiate between Crohn's disease and ulcerative colitis.